These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 12833145

  • 1. Feedback inhibition by RALT controls signal output by the ErbB network.
    Anastasi S, Fiorentino L, Fiorini M, Fraioli R, Sala G, Castellani L, Alemà S, Alimandi M, Segatto O.
    Oncogene; 2003 Jul 03; 22(27):4221-34. PubMed ID: 12833145
    [Abstract] [Full Text] [Related]

  • 2. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 3. Signal transduction and oncogenesis by ErbB/HER receptors.
    Marmor MD, Skaria KB, Yarden Y.
    Int J Radiat Oncol Biol Phys; 2004 Mar 01; 58(3):903-13. PubMed ID: 14967450
    [Abstract] [Full Text] [Related]

  • 4. A computational model on the modulation of mitogen-activated protein kinase (MAPK) and Akt pathways in heregulin-induced ErbB signalling.
    Hatakeyama M, Kimura S, Naka T, Kawasaki T, Yumoto N, Ichikawa M, Kim JH, Saito K, Saeki M, Shirouzu M, Yokoyama S, Konagaya A.
    Biochem J; 2003 Jul 15; 373(Pt 2):451-63. PubMed ID: 12691603
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R, Lenferink AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, Tzahar E, Sela M, van Zoelen EJ, Yarden Y.
    Oncogene; 1998 Mar 12; 16(10):1249-58. PubMed ID: 9546426
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Epidermal growth factor receptor (EGFR) signaling in cancer.
    Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS.
    Gene; 2006 Jan 17; 366(1):2-16. PubMed ID: 16377102
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain.
    Fiorentino L, Pertica C, Fiorini M, Talora C, Crescenzi M, Castellani L, Alemà S, Benedetti P, Segatto O.
    Mol Cell Biol; 2000 Oct 17; 20(20):7735-50. PubMed ID: 11003669
    [Abstract] [Full Text] [Related]

  • 12. Herstatin, an autoinhibitor of the epidermal growth factor receptor family, blocks the intracranial growth of glioblastoma.
    Staverosky JA, Muldoon LL, Guo S, Evans AJ, Neuwelt EA, Clinton GM.
    Clin Cancer Res; 2005 Jan 01; 11(1):335-40. PubMed ID: 15671564
    [Abstract] [Full Text] [Related]

  • 13. Pathogenic poxviruses reveal viral strategies to exploit the ErbB signaling network.
    Tzahar E, Moyer JD, Waterman H, Barbacci EG, Bao J, Levkowitz G, Shelly M, Strano S, Pinkas-Kramarski R, Pierce JH, Andrews GC, Yarden Y.
    EMBO J; 1998 Oct 15; 17(20):5948-63. PubMed ID: 9774339
    [Abstract] [Full Text] [Related]

  • 14. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease.
    Gilbertson RJ, Bentley L, Hernan R, Junttila TT, Frank AJ, Haapasalo H, Connelly M, Wetmore C, Curran T, Elenius K, Ellison DW.
    Clin Cancer Res; 2002 Oct 15; 8(10):3054-64. PubMed ID: 12374672
    [Abstract] [Full Text] [Related]

  • 15. Gene 33 is an endogenous inhibitor of epidermal growth factor (EGF) receptor signaling and mediates dexamethasone-induced suppression of EGF function.
    Xu D, Makkinje A, Kyriakis JM.
    J Biol Chem; 2005 Jan 28; 280(4):2924-33. PubMed ID: 15556944
    [Abstract] [Full Text] [Related]

  • 16. Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signaling.
    Löbke C, Laible M, Rappl C, Ruschhaupt M, Sahin O, Arlt D, Wiemann S, Poustka A, Sültmann H, Korf U.
    Proteomics; 2008 Apr 28; 8(8):1586-94. PubMed ID: 18351692
    [Abstract] [Full Text] [Related]

  • 17. Suppressors of T-cell receptor signaling Sts-1 and Sts-2 bind to Cbl and inhibit endocytosis of receptor tyrosine kinases.
    Kowanetz K, Crosetto N, Haglund K, Schmidt MHH, Heldin CH, Dikic I.
    J Biol Chem; 2004 Jul 30; 279(31):32786-95. PubMed ID: 15159412
    [Abstract] [Full Text] [Related]

  • 18. Loss of RALT/MIG-6 expression in ERBB2-amplified breast carcinomas enhances ErbB-2 oncogenic potency and favors resistance to Herceptin.
    Anastasi S, Sala G, Huiping C, Caprini E, Russo G, Iacovelli S, Lucini F, Ingvarsson S, Segatto O.
    Oncogene; 2005 Jun 30; 24(28):4540-8. PubMed ID: 15856022
    [Abstract] [Full Text] [Related]

  • 19. Dominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2. Both ErbB-1 and ErbB-2 contribute significantly to tumorigenicity.
    Fernandes AM, Hamburger AW, Gerwin BI.
    Am J Respir Cell Mol Biol; 1999 Dec 30; 21(6):701-9. PubMed ID: 10572067
    [Abstract] [Full Text] [Related]

  • 20. Chk1-mediated phosphorylation of receptor-associated late transducer at serine 250 increases its stability by stimulating its interaction with 14-3-3.
    Takeda K, Takata T, Kawai Y, Ishigaki Y, Kajinami K.
    Genes Cells; 2013 May 30; 18(5):369-86. PubMed ID: 23432726
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.